- Home
- RARE vs CNTA Comparison
RARE vs CNTA Comparison
Compare RARE & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- CNTA
- Stock Information
- Founded
- RARE 2010
- CNTA 2020
- Country
- RARE United States
- CNTA United Kingdom
- Employees
- RARE N/A
- CNTA N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- RARE Health Care
- CNTA Health Care
- Exchange
- RARE Nasdaq
- CNTA Nasdaq
- Market Cap
- RARE 2.6B
- CNTA 2.3B
- IPO Year
- RARE 2014
- CNTA 2021
- Fundamental
- Price
- RARE $29.96
- CNTA $16.64
- Analyst Decision
- RARE Strong Buy
- CNTA Strong Buy
- Analyst Count
- RARE 14
- CNTA 10
- Target Price
- RARE $86.64
- CNTA $30.56
- AVG Volume (30 Days)
- RARE 1.4M
- CNTA 1.0M
- Earning Date
- RARE 08-05-2025
- CNTA 08-12-2025
- Dividend Yield
- RARE N/A
- CNTA N/A
- EPS Growth
- RARE N/A
- CNTA N/A
- EPS
- RARE N/A
- CNTA N/A
- Revenue
- RARE $610,159,000.00
- CNTA $15,000,000.00
- Revenue This Year
- RARE $19.72
- CNTA N/A
- Revenue Next Year
- RARE $23.29
- CNTA N/A
- P/E Ratio
- RARE N/A
- CNTA N/A
- Revenue Growth
- RARE 26.77
- CNTA 118.88
- 52 Week Low
- RARE $25.81
- CNTA $9.60
- 52 Week High
- RARE $60.37
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- RARE 53.11
- CNTA 49.69
- Support Level
- RARE $29.04
- CNTA $16.27
- Resistance Level
- RARE $30.61
- CNTA $16.84
- Average True Range (ATR)
- RARE 0.80
- CNTA 0.70
- MACD
- RARE 0.31
- CNTA -0.21
- Stochastic Oscillator
- RARE 79.81
- CNTA 16.93
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.